Old Web
English
Sign In
Acemap
>
authorDetail
>
J. Chih-Hsin Yang
J. Chih-Hsin Yang
National Taiwan University
Medicine
Oncology
Internal medicine
Pembrolizumab
first line
4
Papers
1
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
OFP01.02 KEYNOTE-021 Cohort G Long-Term Follow-up: First-Line (1L) Pemetrexed and Carboplatin (PC) with or without Pembrolizumab for Advanced Nonsquamous NSCLC
2021
Journal of Thoracic Oncology
Mark M. Awad
Shirish M. Gadgeel
Hossein Borghaei
Amita Patnaik
J. Chih-Hsin Yang
Steven Francis Powell
Ryan D. Gentzler
Renato Martins
James P. Stevenson
Mehmet Altan
Shadia I. Jalal
Amit Panwalkar
Matthew A. Gubens
L.V. Sequist
Sanatan Saraf
B. Zhao
Bilal Piperdi
Corey J. Langer
Show All
Source
Cite
Save
Citations (0)
MO01.36 Afatinib in Asian and Non-Asian Patients (pts) with EGFR Mutation-Positive (EGFRm+) NSCLC Harboring Major Uncommon Mutations
2021
Journal of Thoracic Oncology
J. Chih-Hsin Yang
Martin Schuler
Sanjay Popat
S. Miura
S. Heeke
Antonio Passaro
F. De Marinis
K. Park
Edward S. Kim
Show All
Source
Cite
Save
Citations (0)
MO01.22 Canakinumab as Adjuvant Therapy in Patients with Completely Resected Non-Small Cell Lung Cancer (NSCLC): CANOPY-A Trial
2021
Journal of Thoracic Oncology
Alexander I. Spira
A. Ardizzoni
Fabrice Barlesi
B.C. Cho
P. De Marchi
Yasushi Goto
Dariusz M. Kowalski
Shun Lu
Luis Paz-Ares
David R. Spigel
Marlene Thomas
Mimi Leung
Jason Baum
W. Zhou
S. Portella
J. Chih-Hsin Yang
Edward B. Garon
Show All
Source
Cite
Save
Citations (0)
P1.01-112 Phase 3, Randomized, Double-Blind Trial of First-Line Pembrolizumab With or Without Lenvatinib in Metastatic NSCLC: LEAP-007
2019
Journal of Thoracic Oncology
Tarek Mekhail
S.-H. Kim
Kaoru Kubota
M. González Del Riego
L. Wu
A. Samkari
T.M. Fouad
J. Chih-Hsin Yang
Show All
Source
Cite
Save
Citations (1)
1